Latest Conference Coverage


What to Expect from the 2021 MDA Clinical and Scientific Conference: Sharon Hesterlee, PhD

What to Expect from the 2021 MDA Clinical and Scientific Conference: Sharon Hesterlee, PhD

March 12th 2021

The executive vice president and chief research officer of the MDA gave an overview of the upcoming virtual annual meeting and her insight on what to look for.


Next Steps in Improving Autoimmune Encephalitis Care

Next Steps in Improving Autoimmune Encephalitis Care

March 11th 2021

The assistant professor of neurology at Mayo Clinic detailed the areas of autoimmune encephalitis research that need more attention, as well as the diagnostic potential of autoantibody assays.


Yujie Wang, MD

Investigating the 1-Hour Post-Infusion Monitoring Period: Yujie Wang, MD

March 11th 2021

The neurologist from the University of Washington Medical Center discussed how the study of natalizumab adverse events came about and the importance of this monitoring period.


Evan Luxenberg, MD

Older Patients With MS Face Additional Risks With Ocrelizumab Treatment

March 10th 2021

The retrospective analysis in patients aged 55 years and older underlines the importance of testing different patient populations.


Stephanie Blandford, MSc

Interleukin-1 Receptor Antagonism and Multiple Sclerosis: Stephanie Blandford, MSc

March 10th 2021

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed further research she would like to see conducted with IL-1RA in MS.


Carlos Perez, MD

African American Patients Have Higher MS Disability Scores Than Hispanic, Caucasian Patients

March 9th 2021

Researchers found that, in an exploratory analysis of 150 patients, African American patients with MS were most likely to become disabled and lose employment.


 Ishu Arpan, PT, PhD

Identifying Those at Risk of Falling in Multiple Sclerosis

March 8th 2021

Ishu Arpan, PhD, senior research associate at Oregon Health & Science University, discussed her team’s investigations into identifying patients with MS at risk of falling.


Fatigue Severely Impacts Quality of Life, Work Productivity in MS

Fatigue Severely Impacts Quality of Life, Work Productivity in MS

March 7th 2021

Patients having a relapse, confirmed disability accumulation, or worsening in fatigue had significant negative impact on each of the work productivity and activity impairment measures.


Ilena George, MD

Prescribing DMT in Radiologically Isolated Syndrome: Ilena George, MD

March 7th 2021

The neurologist from Massachusetts General Hospital discussed physician rationales behind prescribing DMT use in RIS.


Understanding the Momentum in the Autoimmune Encephalitis Research Community

Understanding the Momentum in the Autoimmune Encephalitis Research Community

March 5th 2021

The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.


African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients

African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients

March 4th 2021

Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.


How COViMS Registry Is Clarifying MS COVID-19 Risks: Amber Salter, MPH, PhD

How COViMS Registry Is Clarifying MS COVID-19 Risks: Amber Salter, MPH, PhD

March 4th 2021

The assistant professor of biostatistics at Washington University in St. Louis discussed what role the COViMS registry can play for the MS community at this stage in the pandemic.


Julia Luo

Human Oligodendrocyte Differences Due to Environmental Signals Rather Than Lineage

March 4th 2021

Researchers used single-cell RNA sequencing on adult, pediatric, and infant surgical tissues to study oligodendrocyte types in order to better understand multiple sclerosis.


Spencer Hutto, MD

High Rates of MS Relapse after TNFα Inhibitor Discontinuation: Spencer Hutto, MD

March 3rd 2021

The fellow of autoimmune neurology at Massachusetts General Hospital discusses the ongoing question about whether the demyelination is an unmasking of disease or consequence of the treatment.


Stephanie Blandford, MSc

Predicting MS Disability With IL-1 Receptor Antagonist Levels: Stephanie Blandford, MSc

March 3rd 2021

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed her team’s investigations into the use of IL-1RA as a biomarker for MS disability.


NeuroVoices: Dylan Rice, on Improving Adherence to MS DMTs

NeuroVoices: Dylan Rice, on Improving Adherence to MS DMTs

March 3rd 2021

The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.


Expanding Research in Autoimmune Encephalitis: Divyanshu Dubey, MBBS

Expanding Research in Autoimmune Encephalitis: Divyanshu Dubey, MBBS

March 2nd 2021

The assistant professor of neurology at Mayo Clinic provided his thoughts on the next steps in understanding autoimmune encephalitis and the direction that research must pivot to.


Remote Technology Improves Adherence Rates in Relapsing MS

Remote Technology Improves Adherence Rates in Relapsing MS

March 2nd 2021

The authors expanded upon the notion that nonadherence to oral DMTs is more nuanced than simply missing doses.


Stephanie Blandford, MSc, PhD candidate

IL-1RA Biomarker Predicts Disability in Multiple Sclerosis

March 1st 2021

The researchers found that interleukin-1 receptor antagonist levels in plasma correlated with neurofilament light levels in cerebrospinal fluid.


Unmet Needs in the Multiple Sclerosis Community: Luc Truyen, MD, PhD

Unmet Needs in the Multiple Sclerosis Community: Luc Truyen, MD, PhD

March 1st 2021

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.


Prevalence of Autoimmune Encephalitis: Divyanshu Dubey, MBBS

Prevalence of Autoimmune Encephalitis: Divyanshu Dubey, MBBS

February 28th 2021

The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.


 Ilena George, MD

Increasing Prevalence of Early DMT Prescription in Radiologically Isolated Syndrome

February 27th 2021

Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.


Fingolimod Shows Potential to Reduce Retinal Neurodegeneration in Relapsing MS

Fingolimod Shows Potential to Reduce Retinal Neurodegeneration in Relapsing MS

February 27th 2021

The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.

© 2025 MJH Life Sciences

All rights reserved.